RxDoctor Payments Data

Hilary Young, PA

Physician Assistant · Cleveland, OHNPI 1013379601

Payments from drug & device makers

$6,849in general payments, 2019–2025

Across 156 payments — averaging $43.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • Novartis$1K
  • TG Therapeutics, Inc.$1K
  • Banner Life Sciences, LLC$988
  • Sanofi$424
  • EMD Serono, Inc.$370
  • plus $850 from 7 others

What the payments were for

  • Consulting fees$5007%
  • Speaking & faculty fees$90013%
  • Food & beverage$5,24277%
  • Education$2073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,849 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$9,613
Medicare patients
69
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate26$173,462
Dimethyl Fumarate33$4,668
Baclofen217$4,595
Modafinil48$3,750
Gabapentin205$3,591
Dalfampridine ErDalfampridine35$2,530
Tizanidine Hcl120$1,515
AmantadineAmantadine Hcl35$1,396
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine44$1,229
Pregabalin35$1,018
Oxybutynin Chloride16$627
Clonazepam33$499
NitrofurantoinNitrofurantoin Macrocrystal11$478
Oxybutynin Chloride ErOxybutynin Chloride31$467
Amitriptyline Hcl13$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$2,092$173,46226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →